In this episode Doctors Jam & Sally explain CAR-T cell therapy for myeloma - how it works, what the treatment journey looks like, the potential side effects, and why it offers hope for longer treatment-free time.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/

The Myeloma UK InfoLine is: 0800 980 3332

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode explains the new NICE-approved combination of belantamab, pomalidomide and dexamethasone for people whose myeloma has relapsed after first-line treatment, including benefits, side effects and how treatment decisions are made.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/

The Myeloma UK InfoLine is: 0800 980 3332

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode looks ahead to 2026, exploring upcoming myeloma treatments, major research advances, and the topics patients and carers most want to understand.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/

The Myeloma UK InfoLine is: 0800 980 3332

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Dr Jam Katari and Dr Sally Moore are joined by leading myeloma experts to look back on 2025’s biggest breakthroughs; from functional cures and new treatments to patient-friendly innovations.

This is part 2 of a seasonal special, featuring Professor Karthik Ramasamy and Dr. Ceri Bygrave. To hear the first part, please follow this link: Part1

Functional cure is no longer just a dream — it’s becoming part of everyday myeloma care.

New drugs and smarter treatment combinations are transforming survival and quality of life.

Innovation is making treatment easier — even down to a “Satsuma-sized” on-body injection device!

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/

The Myeloma UK InfoLine is: 0800 980 3332

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Dr Jam Katari and Dr Sally Moore are joined by leading myeloma experts to look back on 2025’s biggest breakthroughs; from early treatment for smouldering myeloma to cutting-edge CAR-T therapy made inside the body.

This is part 1 of a seasonal special, featuring Professor Karthik Ramasamy and Dr. Ceri Bygrave. Please ensure you listen to our second part next week.

Early action: Could treating smouldering myeloma stop the disease before it starts?

Sharper tools: New genetic tests are redefining what “high-risk” myeloma really means.

Future now: “In vivo” CAR-T therapy turns your own body into the treatment factory—real-life medical sci-fi!

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

We are proudly partnered with Myeloma UK for this episode. For more credible myeloma advice, please visit: https://www.myeloma.org.uk/

The Myeloma UK InfoLine is: 0800 980 3332

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode introduces Talquetamab - a newly approved bispecific antibody for relapsed myeloma - explaining how it works, who it’s for, and what side effects patients should expect and prepare for.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Sean Molloy, renown spinal surgeon at the Royal National Orthopaedic Hospital (RNOH) NHS Trust in Stanmore explains how tailored bracing, breakthrough bone healing in myeloma, physiotherapy and minimally invasive vertebroplasty can transform pain, mobility and long-term spinal stability.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Dr Jam & Sally unpack what neuropathy is, why it happens in myeloma treatment, and how patients can recognise, prevent and manage it to protect their quality of life.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

Dr Jam & Sally unpack what remission, relapse and refractory disease truly mean for people living with myeloma — and explore how close we are to talking about cure.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.

This episode unpacks the complex world of myeloma genetics - what high and standard risk really mean, how these tests guide treatment, and how future advances could lead to truly personalised care with Sarah Gooding.

Sarah is a colleague, and an Honorary Consultant Haematologist, based in Oxford.

📌Key Takeaways:

For extra content and more resources, please visit our website: https://www.themyelomaminutes.com/

This podcast is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for personalised medical guidance regarding your health concerns

ABOUT YOUR HOSTS

Dr. Jam Kothari

Dr Jam Kothari (@myeloma_medic) is an Oxford based blood cancer doctor, specialising in the treatment of multiple myeloma and associated conditions. He has been a consultant for a decade, and leads the provision of myeloma care for Oxford and neighbouring areas. He lectures regionally and nationally and leads clinical trials investigating the use of new treatments for myeloma. He is a strong believer in patient based, holistic care, delivered with warmth, clarity and integrity.

Dr. Sally Moore

Dr Sally Moore is a Bristol based consultant who specialises in treating patients living with multiple myeloma and other plasma cell disorders. She oversees the delivery of clinical research studies for myeloma patients and has academic interests in how to maximise quality of life for patients and improve outcomes in older, less fit patients.  She frequently contributes to myeloma related educational events for fellow doctors and healthcare professionals at a local, regional and national level and is an active member of the UK Myeloma Research Alliance and an executive member of the UK Myeloma Society.